Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Boris Johnson sacks Michael Gove as even allies tell him ‘game’s up’
    • Federal Reserve officials warn entrenched inflation poses ‘significant risk’
    • New Covid variants threaten China’s mRNA vaccine hopes
    • US and UK intelligence chiefs call for vigilance on China’s industrial spies
    • Boris Johnson’s replacement: runners and riders
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Federal Reserve officials warn entrenched inflation poses ‘significant risk’
    • America’s unending horizon of mass shootings
    • Crypto collapse reverberates widely among black American investors
    • US retailers ditch talk of ‘Roaring Twenties’ boom amid consumer pinch
    • Judge holds Cushman & Wakefield in contempt in New York Trump probe
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • French state plans to take full control of EDF
    • US retailers ditch talk of ‘Roaring Twenties’ boom amid consumer pinch
    • EY boosts accountancy title inflation by dubbing senior staff ‘partner’
    • BA to cut another 10,300 flights escalating airline disruption
    • KPMG’s business in UAE split by partner infighting and coup attempt
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Live news updates: Samsung profits miss forecasts as inflation dents demand
    • Live news updates: More than 30 members of UK government quit, heaping pressure on Boris Johnson
    • Treasury yields rise after Fed minutes show inflation concern
    • Pound traders look past UK political turmoil
    • US bond market flashes warning signal of economic slowdown
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • America’s unending horizon of mass shootings
    • Boris Johnson’s era is at an end as Tories rush for the exit
    • It’s over for Boris Johnson as Tories rush to save themselves
    • Why Eric Schmidt believes bioscience will change the world
    • The departure of Boris Johnson is long overdue
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Michael Lewis: ‘The thing that really works for Trump is: the system’s rigged’
    • Meet the founders with the boomerang factor
    • Pop-up leaders and flexible staff are ready for a new crisis
    • British Rail: A New History — a timely reminder of how to run a railway
    • Help truly wanted, even if you’ve been in jail
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Chess: Nepo wins Candidates again as Carlsen asks for new world title format
    • Why Eric Schmidt believes bioscience will change the world
    • The fantastic spending habits of Mr Roald Dahl
    • Thor: Love and Thunder film review — a droll Marvel sequel aware of its own absurdity
    • Hot property: five homes for sale in the Pacific Northwest
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Drugs research

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 27 June, 2022
    Covid-19 vaccines
    Pause in medication would improve Covid jab response for millions, study shows

    Short break in immune suppression treatment improves antibody production after vaccination while doing little harm

  • Tuesday, 14 June, 2022
    The Big Read
    BioNTech’s second act: can it transform the fight against cancer?

    The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven

  • Friday, 10 June, 2022
    Pharmaceuticals sector
    GSK hopes for boost from respiratory virus jab

    Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline

  • Wednesday, 8 June, 2022
    Quest for pill to stall Parkinson’s disease takes step forward

    Drug from Denali Therapeutics offers hope for sufferers of degenerative brain disorder

  • Wednesday, 8 June, 2022
    LexBioNTech
    BioNTech/pancreatic cancer: mRNA jabs may tame a savage disease Premium content

    German biotech’s promising early-stage results make it a sought-after partner

  • Wednesday, 1 June, 2022
    Indivior sees ‘huge opportunity’ for drug targeting cannabis misuse

    Biotech company hopes to win first US approval for medicine aimed at people addicted to marijuana

  • Thursday, 26 May, 2022
    Special ReportFT Health Centre
    FT Health: Future of Antibiotics

    The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain

  • Thursday, 26 May, 2022
    Special ReportFT Health: Future of Antibiotics
    Vaccines hold potential to curb antibiotic resistance

    Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant

  • Monday, 9 May, 2022
    Covid-19 vaccines
    BioNTech beats forecasts on back of Covid vaccine demand

    German biotech maintains guidance but prepares for fall in sales because of jab oversupply

  • Friday, 29 April, 2022
    LexEli Lilly & Co
    Obesity treatments: hunger-suppressing drugs whet investors’ appetite Premium content

    On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets

  • Thursday, 28 April, 2022
    Eli Lilly says obesity drug has similar results to weight-loss surgery

    Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker

  • Tuesday, 26 April, 2022
    Special Report
    FT Health: Innovation in Healthcare

    The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy

  • Tuesday, 26 April, 2022
    Special ReportFT Health: Innovation in Healthcare
    Streamlined EU process promises faster access to breakthrough drugs

    ‘Intricate dance’ under way to ensure simplified assessments of new medicines maintain quality and integrity

  • Tuesday, 12 April, 2022
    Antibiotic resistance
    How will UK’s fixed-fee scheme for antibiotics help tackle the growing health crisis?

    Move could boost global development of drugs to ease antimicrobial resistance

  • Monday, 7 March, 2022
    Special ReportFT Health: Future of Antibiotics
    How pharma economics hold back antibiotic development

    New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say

  • Tuesday, 22 February, 2022
    Pharmaceuticals sector
    Nimble UK regulator is a draw for drugmakers, says former vaccines chief

    Kate Bingham urges fund managers to step up investment in life sciences

  • Friday, 28 January, 2022
    Sally Davies
    It’s time to confront the pandemic of antibiotic resistance

    To save lives and economies, we must make progress by drawing on lessons from Covid-19

  • Monday, 10 January, 2022
    Coronavirus treatment
    Novartis to seek speedy approval for Covid drug after positive trials

    Swiss drugmaker to license antiviral therapeutic after success in early-stage tests

  • Wednesday, 5 January, 2022
    Pfizer Inc
    Pfizer and BioNTech team up to develop mRNA-based shingles vaccine

    Drugmakers set to take on GSK as they aim to replicate Covid jab success

  • Tuesday, 4 January, 2022
    ExplainerCoronavirus pandemic
    Long Covid: why do some people have symptoms months after infection?

    Researchers say more than 100m suffer ill effects for at least 12 weeks

  • Thursday, 30 December, 2021
    UK life sciences lobby calls for investment in antivirals to fight Covid

    Lower effectiveness of vaccines against Omicron makes need for antivirals more urgent, says UK BioIndustry Association chair

  • Wednesday, 8 December, 2021
    Covid-19 vaccines
    Pfizer says three vaccine doses offer protection against Omicron

    Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant

  • Sunday, 5 December, 2021
    Kate Bingham
    Covid has given UK biotech a lesson — and a legacy

    Good venture capitalism should build companies up, developing medicines that deliver public good and profit

  • Tuesday, 23 November, 2021
    AstraZeneca PLC
    Pascal Soriot links AstraZeneca jab to low UK hospitalisations

    Chief executive says more data needed to explain Europe’s higher rate of admissions

  • Tuesday, 23 November, 2021
    AstraZeneca PLC
    AstraZeneca calls on UK to increase science investment

    Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In